Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.
(Agrylin)
469 results
  • A Young Adult With Essential Thrombocythemia Presenting as Myocardial Infarction. [Case Reports]
    Cureus. 2022 Sep; 14(9):e28883.Ganta N, Prasad A, … Cheriyath P
  • Essential thrombocythemia (ET) is a myeloproliferative neoplasm involving the clonal proliferation of platelets. It is Philadelphia negative and is associated with Janus kinase 2 (JAK2), calreticulin (CALR), or myeloproliferative leukemia virus oncogene (MPL) mutations. The resultant platelets have quantitative and qualitative defects, making them more sticky and prone to thromboembolism. However…
  • Anagrelide in essential thrombocythemia: Efficacy and long-term consequences in young patient population. [Journal Article]
    Leuk Res. 2022 12; 123:106962.Bieniaszewska M, Sobieralski P, … Dutka M
  • According to the current treatment recommendations, anagrelide, an oral antiplatelet agent, is recommended as a second-line therapy for patients with high-risk essential thrombocythemia experiencing intolerance or refractoriness to first-line approach, such as hydroxyurea or pegylated interferon alpha-2a. If there is a need for introduction of cytoreductive treatment in young patients with a pers…
  • Surgical Complications in Myeloproliferative Neoplasm Patient with Essential Thrombocythemia: A Case Report. [Case Reports]
    Int Med Case Rep J. 2022; 15:491-497.Rinaldi I, Muthalib A, … Winston K
  • CONCLUSIONS: Myeloproliferative disease patients with high thrombocyte count are subjected to increased risk of thrombotic complications in perioperative settings, thus perioperative management and risk assessment are important to improve quality of life and prevent complications. Surgery in MPN patients with elevated thrombocytes may be considered if the benefits outweigh the risks. More studies in this field should be conducted in-order to provide more data for a guideline or systematic review/meta-analyses.
  • CDH6 as a prognostic indicator and marker for chemotherapy in gliomas. [Journal Article]
    Front Genet. 2022; 13:949552.Meng M, Zhou H, … Wang S
  • Glioma is the most malignant cancer of the central nervous system. There are various therapies for treating gliomas, but their outcomes are not satisfactory. Therefore, new targets for glioma treatment are needed. This study examined the cadherin-6 (CDH6) expression in gliomas using The Cancer Genome Atlas and Chinese Glioma Genome Atlas datasets. CDH6 expression positively correlated with the Wo…
  • Anagrelide-Induced Supraventricular Tachycardia: A Case Report. [Case Reports]
    Cureus. 2022 Jun; 14(6):e26119.Badar F, Azeez H, … Iftikhar A
  • Anagrelide is an inhibitor of the phosphodiesterase-3 (PDE-3) enzyme that suppresses megakaryocytes; hence it is used in the treatment of essential thrombocythemia. Anagrelide can cause positive inotropic and chronotropic effects on the cardiovascular system. Its cardiovascular side effects are rare and include palpitations, tachyarrhythmias, cardiomyopathy, angina, and heart failure. We report t…
  • Platelet Anti-Aggregator Drowns the Heart. [Case Reports]
    S D Med. 2021 Nov; 74(11):502-505.Siddiqui MU, Siddiqui MD, … Siddiqui M
  • CONCLUSIONS: Anagrelide is considered to be very effective treatment for essential thrombocytosis. It is, however, associated with serious adverse effects such as pericardial effusion, liver toxicity and palpitations. The mechanisms of these adverse drug reactions are still not completely understood. We suggest that patient taking anagrelide presenting with shortness of breath should have a transthoracic echocardiogram performed to rule out pericardial effusion. Liver enzymes should also be monitored closely and anagrelide discontinued immediately if the above-mentioned adverse events are noted.
  • Bone marrow morphological features and therapy in patients with Philadelphia-negative neoplasms. [Review]
    Expert Rev Hematol. 2021 09; 14(9):841-850.Pich A, Beggiato E, … Benevolo G
  • Introduction Chronic myeloproliferative neoplasm (MPNs) are clonal malignant bone marrow (BM) diseases, arising from a hematopoietic stem cell. All therapies for these neoplasms have peculiar effects on the bone marrow, but little evidence has been described in the literature.Areas covered This review examines BM morphological changes following the main treatments in Philadelphia-negative MPNs. H…
  • Essential Thrombocythemia in Children: A Retrospective Study. [Journal Article]
    J Hematol. 2021 Jun; 10(3):106-113.Ameen M, Siddiqui K, … Al-Musa A
  • CONCLUSIONS: The incidence of ET in children is extremely low in Saudi Arabia. Most of the children with ET were asymptomatic, and thrombocytosis was often discovered incidentally. JAK2 V617F mutation has no known impact on the prognosis or on the outcome of the disease in the pediatric age group that is in contrast to the adult ET. Children less than 1 year are at high risk for complications particularly during acute precipitating infectious episode. The potential complications and clinical course of pediatric ET are unpredictable.
  • Advances in the Treatment of Polycythemia Vera: Trends in Disease Management. [Review]
    Cureus. 2021 Mar 30; 13(3):e14193.Arya Y, Syal A, … Gaba S
  • Treatment modalities for polycythemia vera (PV) have evolved over time. Phlebotomy and low-dose aspirin suffice in low-risk patients, but cytoreductive therapies are indicated in all high-risk patients (age ≥ 65 years or those with a history of PV-related thrombotic event) and may be considered for low-risk patients with progressively increasing splenomegaly, progressively increasing leucocyte an…
  • Leg ulcer with long-term hydroxyurea use. [Journal Article]
    Clin Case Rep. 2021 Apr; 9(4):2487-2488.Ammad Ud Din M, Hussain SA, Jamshed S
  • Long-term use of hydroxyurea can cause leg ulcers which usually do not heal unless the drug is discontinued. Patients should be counseled regarding alternative lines of treatment like anagrelide and pegylated-interferon.
New Search Next